UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2206-10
Program Prior Authorization/Medical Necessity
Medication *Tremfya® (guselkumab)
*This program applies to the subcutaneous formulations of Tremfya
P&T Approval Date 5/2020, 11/2020, 6/2021, 12/2021, 12/2022, 3/2023, 7/2023, 10/2024,
11/2024, 3/2025
Effective Date 5/1/2025
1. Background:
Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of adult
patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or
phototherapy, active psoriatic arthritis, moderately to severely active ulcerative colitis, and
moderately to severely active Crohn’s disease.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Tremfya will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) One of the following:
(a) All of the following:
i. Greater than or equal to 3% body surface area involvement, palmoplantar,
facial, genital involvement, or severe scalp psoriasis
-AND-
ii. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial):
a. Corticosteroids (e.g., betamethasone, clobetasol, desonide)
b. Vitamin D analogs (e.g., calcitriol, calcipotriene)
c. Tazarotene
d. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
e. Anthralin
f. Coal tar
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
iii. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of plaque psoriasis as documented by claims
history or submission of medical records (Document drug, date, and duration
of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast),
Skyrizi (risankizumab), ustekinumab].
-OR-
(c) Both of the following:
i. Patient is currently on Tremfya therapy as documented by claims history or
submission of medical records (Document date and duration of therapy)
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
the prescriber’s office, or any form of assistance from the Janssen
sponsored CarePath Savings program (e.g., sample card which can be
redeemed at a pharmacy for a free supply of medication) as a means to
establish as a current user of Tremfya*
-AND-
(3) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq
(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
-AND-
(4) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt
of a manufacturer supplied sample at no cost in the prescriber’s office or any form of
assistance from the Janssen sponsored CarePath Savings program shall be required to
meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
2
2. Reauthorization
a. Tremfya will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq
(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Tremfya will be approved based on all of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) One of the following:
(a) History of failure to a 3 month trial of methotrexate at the maximally indicated
dose, unless contraindicated or clinically significant adverse effects are
experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of psoriatic arthritis as documented by claims
history or submission of medical records (Document drug, date, and duration
of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab),
ustekinumab, Xeljanz (tofacitinib), Otezla (apremilast), Rinvoq
(upadacitinib)].
-OR-
(c) Both of the following:
i. Patient is currently on Tremfya therapy as documented by claims history or
submission of medical records (Document date and duration of therapy)
-AND-
© 2025 UnitedHealthcare Services, Inc.
3
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Janssen sponsored
CarePath Savings program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Tremfya*
-AND-
(3) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt
of a manufacturer supplied sample at no cost in the prescriber’s office or any form of
assistance from the Janssen sponsored CarePath Savings program shall be required to
meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Tremfya will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
C. Ulcerative Colitis (UC)
1. Initial Authorization for Maintenance Dosing
© 2025 UnitedHealthcare Services, Inc.
4
a. Tremfya will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) One of the following:
(a) Patient has been established on therapy with Tremfya under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
moderately to severely active ulcerative colitis
-OR-
(b) Both of the following:
i. Patient is currently on Tremfya therapy for moderately to severely active
ulcerative colitis as documented by claims history or submission of
medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Janssen sponsored
CarePath Savings program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Tremfya*
-AND-
(3) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi
(risankizumab)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the receipt
of a manufacturer supplied sample at no cost in the prescriber’s office or any form of
assistance from the Janssen sponsored CarePath Savings program shall be required to
meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Tremfya will be approved based on both of the following criteria:
© 2025 UnitedHealthcare Services, Inc.
5
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi
(risankizumab)]
Authorization will be issued for 12 months.
D. Crohn’s Disease (CD)
1. Initial Authorization
a. Tremfya will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) One of the following:
(a) Patient has been established on therapy with Tremfya under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
moderately to severely active Crohn’s disease
-OR-
(b) One of the following:
i. History of failure to one of the following conventional therapies at up to
maximally indicated doses, unless contraindicated or clinically significant
adverse effects are experienced (document drug, date, and duration of
trial):
• Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
• 6-mercaptopurine (Purinethol)
• Azathioprine (Imuran)
• Methotrexate (Rheumatrex, Trexall)
-OR-
ii. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of Crohn’s disease as documented by
claims history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., adalimumab, Cimzia (certolizumab), Entyvio
(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib),
Skyrizi (risankizumab), ustekinumab]
© 2025 UnitedHealthcare Services, Inc.
6
-OR-
(c) Both of the following:
i. Patient is currently on Tremfya therapy for moderately to severely active
Crohn’s disease as documented by claims history or submission of medical
records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Janssen sponsored
CarePath Savings program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Tremfya*
-AND-
(3) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Entyvio
(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Skyrizi
(risankizumab), ustekinumab]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the receipt
of a manufacturer supplied sample at no cost in the prescriber’s office or any form of
assistance from the Janssen sponsored CarePath Savings program shall be required to
meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Tremfya will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Entyvio
(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Skyrizi
(risankizumab), ustekinumab]
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
7
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Tremfya [package insert]. Horsham, PA: Janssen Biotech Inc.; September 2024.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment
of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with
an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of
psoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update
2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol
2015;29:2277-94.
8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care
for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the
treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based
conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.
9. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the
management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-
72.
Program Prior Authorization/Medical Necessity - Tremfya (guselkumab)
Change Control
5/2020 New program
11/2020 Added review criteria for psoriatic arthritis due to new indication.
Updated background and references.
6/2021 Removed preceding month requirement from failure criteria. Added
coverage criteria for patients previously treated with a biologic
© 2025 UnitedHealthcare Services, Inc.
8
DMARD. Removed prescriber requirement from reauthorization
criteria. Added clarification that submission of medical records is
required documenting previous or current therapy with a biologic
DMARD in order to bypass step through non-biologic therapies if claim
history not available.
12/2021 Updated conventional DMARD bypass language for psoriasis and
psoriatic arthritis with no change to clinical intent. Updated CT/KY
footnote.
12/2022 Annual review with no change to clinical criteria. Added Rinvoq as an
example where appropriate.
3/2023 Updated state mandate footnote to include Mississippi. Updated
examples to adalimumab.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Annual review with no changes to coverage criteria. Updated state
mandate footnote and reference.
11/2024 Added coverage criteria for ulcerative colitis. Updated background and
reference.
3/2025 Added coverage criteria for ulcerative colitis. Updated background.
© 2025 UnitedHealthcare Services, Inc.
9